The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 24, 2019

Filed:

May. 23, 2017
Applicant:

Precision Ibd, Inc., San Diego, CA (US);

Inventors:

Jared Salbato, San Diego, CA (US);

Stefan Westin, San Diego, CA (US);

Nicholas Chi-Kwan Ling, San Diego, CA (US);

Anjali Jain, San Diego, CA (US);

Sharat Singh, San Diego, CA (US);

Assignee:

PRECISION IBD, INC., San Diego, CA (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
G01N 33/537 (2006.01); G01N 33/58 (2006.01); G01N 33/94 (2006.01); C07K 14/54 (2006.01); C07K 14/705 (2006.01); G01N 33/564 (2006.01); G01N 33/68 (2006.01);
U.S. Cl.
CPC ...
G01N 33/94 (2013.01); C07K 14/5434 (2013.01); C07K 14/70546 (2013.01); G01N 33/537 (2013.01); G01N 33/564 (2013.01); G01N 33/58 (2013.01); G01N 33/6854 (2013.01); C07K 2319/20 (2013.01); C07K 2319/50 (2013.01); G01N 2333/54 (2013.01); G01N 2333/5434 (2013.01); G01N 2333/70546 (2013.01); G01N 2800/065 (2013.01); G01N 2800/52 (2013.01);
Abstract

The present invention provides a sensitive and specific indirect homogeneous mobility shift assay using size exclusion chromatography to measure biologics such as vedolizumab and ustekinumab in a patient sample. The assays of the present invention are particularly advantageous for detecting the presence or level of biologics that target complex or large antigens including cell surface proteins, transmembrane proteins, heavily glycosylated proteins, and multimeric proteins, as well as antigens that cannot be purified, impure antigens, and partially or substantially purified antigens. The present invention also provides isolated soluble α4β7 integrin heterodimers and isolated soluble IL-12p40 monomers that are suitable for use in the indirect assays described herein.


Find Patent Forward Citations

Loading…